A Two Part, Single-Centre, Open-label, Phase I/IIa, Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients With Advanced Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 04 Jul 2019
Price : $35 *
At a glance
- Drugs Efineptakin alfa (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors I-MAB Biopharma
- 05 Mar 2019 According to an I-MAB Biopharma media release, the first patient has been dosed in this trial.
- 05 Mar 2019 Status changed from planning to recruiting, as reported in an I-MAB Biopharma media release.
- 15 Nov 2018 New trial record